Page 96 - Read Online

Kouroumalis et al. Hepatoma Res 2018;4:34 I http://dx.doi.org/10.20517/2394-5079.2018.33 Page 13 of 18

DECLARATIONS
Authors’ contributions
Devised the review, supervised the project and prepared the final draft: Kouroumalis E
Revised the clinical data and participated in the preliminary draft: Samonakis D
Revised experimental data and participated in the preliminary draft: Notas G

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declare that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2018.

REFERENCES
1. Kim DY, Han KH. Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer 2012;1:2-14.
2. Sifaki-Pistolla D, Karageorgos SA, Koulentaki M, Samonakis D, Stratakou S, Digenakis E, Kouroumalis E. Geoepidemiology of
hepatocellular carcinoma in the island of Crete, Greece. A possible role of pesticides. Liver Int 2016;36:588-94.
3. Petruzziello A. Epidemiology of hepatitis B virus (HBV) and hepatitis C virus (HCV) related hepatocellular carcinoma. Open Virol J
2018;12:26-32.
4. Krulich L, Dhariwal AP, McCann SM. Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release
from rat pituitary in vitro. Endocrinology 1968;83:783-90.
5. Benoit R, Esch F, Bennett HP, Ling N, Ravazzola M, Orci L, Mufson EJ Processing of prosomatostatin. Metabolism 1990;39:22-5.
6. Lamberts SWJ, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. New Engl J Med 1996;334:246-54.
7. Dasgupta P. Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther
2004;102:61-85.
8. Barbieri F, Bajetto A, Pattarozzi A, Gatti M, Wurth R, Thellung S, Corsaro A, Villa V, Nizzari M, Florio T. Peptide receptor targeting in
cancer: the somatostatin paradigm. Int J Pept 2013;2013:926295.
9. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999;20:157-98.
10. Abdel-Rahman O, Lamarca A, Valle JW, Hubner RA. Somatostatin receptor expression in hepatocellular carcinoma: prognostic and
therapeutic considerations Endocr Relat Cancer 2014;21:R485-93.
11. Bruns C,Weckbecker G, Raulf F, Kaupmann K, Schoeffter P, Lubbert H. Molecular pharmacology of somatostatin receptor subtype.
Ann NY Acad Sci 1994;733:138-46.
12. Florio T, Scorizello A, Fattore M, D’Alto V, Salzano S, Rossi G, Berlingieri MT, Fusco A, Schettini G. Somatostatin inhibits PC C13
thyroid cell proliferation through the modulation of phosphotyrosine phophatase activity-impairment of the somatostatinergirc effects
by stable expression of EIA viral oncogene. J Biol Chem 1996;271:6129-36.
13. Møller LN, Stidsenb CE, Hartmann B, Holst JJ. Somatostatin receptors. Biochim Biophys Acta 2003;1616:1-84.
14. Weckbecker G, Raulf F, Stolz B, Bruns C. Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol Ther 1993;60:245-64.
15. Raderer M, Hejna MH, Muller C, Kornek GV, Kurtaran A, Virgolini I, Fiebieger W, Hamilton G, Scheithauer W. Treatment of
hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo. Int J Oncol 2000;16:1197-201.
16. Reynaert H, Rombouts K, Vandermonde A, Urbain D, Kumar U, Bioulac- Sage P, Pinzani M, Rosenbaum J, Geerts A. Expression of
somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut 2004;53:1180-9.
17. Kaemmerer D, Schindler R, Mußbach F, Dahmen U, Altendorf-Hofmann A, Dirsch O, Sänger J, Schulz S, Lupp A. Somatostatin and
CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets.